About us

Redx is a biotech company focused on the discovery and development of novel targeted medicines for the treatment of cancer and fibrotic disease, aiming to progress them to clinical proof of concept (PoC).

Our pipeline

Discovering targeted medicines

Our lead oncology asset, RXC004, is currently in a phase 1 clinical study in patients with advanced malignancies and the company’s ROCK2 selective inhibitor, RXC007, entered a phase 1 clinical study in H1 2021.

Our core capability of converting medicinal chemistry insights into differentiated and commercially attractive small molecule drug candidates has been recognised by others. Over the last three years, Redx has completed four major preclinical stage deals with:

  • AstraZeneca (Porcupine inhibitor, RXC006 up to $377M + royalties)
  • Jazz Pharmaceuticals (Pan-RAF up to $206.5M + royalties)
  • Jazz Pharmaceuticals (two target collaboration: up to $210M per target + royalties)
  • Loxo Oncology /Eli Lilly (BTK inhibitor now progressing successfully in clinic)

Redx research headquarters in Mereside, Alderley Park

View in maps

Our team

Our team of ~50 scientists are based at our labs at Alderley Park, Cheshire, the UK’s largest single site life science campus (near to Manchester). The team is made up of world class medicinal chemistry, biology and clinical capability with deep-rooted biotech and large pharma experience, having generated numerous drug candidates and progressed them through discovery and into the clinic.

Business model and strategy

Exceptional capabilities in medicinal chemistry and translational science are the foundation of Redx. The Company has built an attractive portfolio of assets and has a strong proven track record of drug discovery and development. Over the past three years, it has delivered four major preclinical stage transactions, with further clinical and operational key milestones expected in the future. RXC004 is currently in a phase 1 clinical study in patients with advanced malignancies. The Company’s selective ROCK2 inhibitor, RXC007, also entered a phase 1 clinical study in H1 2021.

Redx has a clear strategy to deliver our ambition of becoming a leading biotech company focused on the discovery and development of targeted medicines in oncology and fibrotic disease, by developing prioritised programmes to clinical proof of concept. With a diverse pipeline and multiple value inflection points, we are confident that we can drive shareholder value through the clinical development of RXC004 and RXC007 as well as our ongoing discovery efforts, where we continue to leverage Redx’s core, proven strengths in medicinal chemistry.

Our discovery business model incorporates our in-house experience and an extensive network of specialist contractors. Our approach is based on three steps:

  1. Select biologically validated targets linked to high unmet medical needs, where we believe there is an opportunity to apply our drug discovery capabilities;
  2. Apply Redx’s molecule design framework, leveraging our strength and experience in medicinal chemistry to optimise a best in class molecule for the target;
  3. Deliver high quality targeted small molecules with a clear line of sight to clinical success.